Protalex Announces Data from Phase 1b Trial of PRTX-100 in Patients with Immune Thrombocytopenia Presented at the European Hematology Association 23rd Annual Meeting June 15, 2018
Protalex Announces Lead Drug Candidate PRTX-100 Reduces Disease Activity in a Mouse Model of Myasthenia Gravis June 12, 2018
Protalex Announces Presentation Highlighting PRTX-100 Phase 1b Clinical Data in Patients with Immune Thrombocytopenia at the European Hematology Association 23rd Annual Meeting May 17, 2018
Protalex Initiates Fourth Cohort Dosing of Phase 1/2 Study of PRTX-100 in Immune Thrombocytopenia April 9, 2018
Protalex Announces Completion of $1.425 Million Private Placement, Recapitalization and Entry into Call Option Agreement with Its Principal Stockholder March 1, 2018
Protalex Doses First Patient in Final and Highest Dose Cohort of European Phase 1b Study of PRTX-100 in Immune Thrombocytopenia January 18, 2018
Protalex Doses First Patient in Fourth Cohort of European Phase 1b Study of PRTX-100 in ITP November 13, 2017
Protalex Announces Publication in the British Journal of Haematology Supporting the Potential of PRTX-100 to Treat Immune Thrombocytopenia October 26, 2017
Protalex Doses First Patient in Third Cohort of European Phase 1b Study of PRTX-100 in ITP August 29, 2017
Protalex Awarded Grant from FDA Office of Orphan Products Development to Foster Clinical Development of PRTX-100 for the Treatment of Immune Thrombocytopenia August 17, 2017
